for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Affimed NV

AFMD.OQ

Latest Trade

5.91USD

Change

-0.03(-0.51%)

Volume

214,380

Today's Range

5.89

 - 

6.08

52 Week Range

3.08

 - 

11.73

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.94
Open
6.05
Volume
214,380
3M AVG Volume
19.80
Today's High
6.08
Today's Low
5.89
52 Week High
11.73
52 Week Low
3.08
Shares Out (MIL)
119.73
Market Cap (MIL)
707.62
Forward P/E
-11.73
Dividend (Yield %)
--

Next Event

Q3 2021 Affimed NV Earnings Release

Latest Developments

More

Affimed Reports Second Quarter 2021 Financial Results

Affimed Reports Q1 2021 Financial Results

Affimed Reports 2020 Financial Results And Highlights Recent Operational Progress

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Affimed NV

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

Industry

Biotechnology & Drugs

Contact Info

Im Neuenheimer Feld 582

69120

Germany

+49.6221.65307

https://www.affimed.com/

Executive Leadership

Thomas Hecht

Independent Chairman of the Supervisory Board

Adi Hoess

Chief Executive Officer, Member of the Management Board

Angus W. Smith

Chief Financial Officer, Co-President Affimed Inc, Member of the Management Board

Wolfgang Fischer

Chief Operating Officer, Member of the Management Board

Arndt Schottelius

Chief Scientific Officer, Member of the Management Board

Key Stats

1.40 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (EUR)

2018

-0.320

2019

-0.500

2020

-0.500

2021(E)

-0.436
Price To Earnings (TTM)
--
Price To Sales (TTM)
14.64
Price To Book (MRQ)
4.04
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
7.45
LT Debt To Equity (MRQ)
7.04
Return on Investment (TTM)
-30.60
Return on Equity (TTM)
-21.87

Latest News

Latest News

BRIEF-Affimed NV Says Announced Completion Of First Dose Cohort In Phase 1/2A Clinical Trial Of AFM24

* AFFIMED NV - ANNOUNCED SUCCESSFUL COMPLETION OF FIRST DOSE COHORT IN PHASE 1/2A CLINICAL TRIAL OF AFM24 Source text for Eikon: Further company coverage:

BRIEF-Affimed Announces Appointment Of Angus Smith As Chief Financial Officer

* AFFIMED ANNOUNCES APPOINTMENT OF ANGUS SMITH AS CHIEF FINANCIAL OFFICER

BRIEF-Affimed Reports 2019 Financial Results And Recent Operational Progress

* AFFIMED REPORTS 2019 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS

BRIEF-Affimed NV Expects Coronavirus Pandemic To Impact Clinical Trials

* AFFIMED NV SAYS PROVIDES UPDATE ON OPERATIONS IN RESPONSE TO CONTINUED SPREAD OF COVID-19 CORONAVIRUS PANDEMIC

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up